Recent Pfizer Press Releases

  • 5/18/16 5:00 pm EDT

    More than 40 accepted abstracts highlight innovation in immuno-oncology and other novel modalities across multiple tumor types

    Pfizer invites public to view and listen to webcast of conference call with analysts on Wednesday, June 8 at 10 a.m. EDT to review oncology business and ASCO data presentations

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the company will have its largest presence to date at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7, with more than 40 abstracts spanning a diverse and growing portfolio seeking to tackle numerous cancers and mechanisms of action. Presentations include eight oral presentations and five poster discussions that span Pfizer’s internal andmore...
  • 5/17/16 8:00 am EDT

    Findings Show the Importance of Patient and Physician Dialogue to Achieve Optimal Disease Management Outcomes

    NEW YORK--(BUSINESS WIRE)--Pfizer announced results from the second phase of its global RA surveys, which assessed the relationship between physician-patient communication and overall RA disease management. The findings from more than 1,700 rheumatologists* in 15 countries builds upon results from the global patient survey findings, released in 2015, involving 3,900 adults living with RA. The combined survey data demonstrate disconnects between patients and physiciansmore...
  • 5/13/16 6:30 am EDT

    Secondary Data Support That TRUMENBA® Protects Against Additional Meningococcal Serogroup B Strains

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains representative of prevalent strains in the U.S. and Europe. The two studies, one in adolescents and one in young adults, met all primary immunogenicity endpoints. Also, secondary data presented show that TRUMENBA demonstrated similar immune responsesmore...
  • 5/11/16 8:00 am EDT
    • Metastatic Research Accounts for Only About 7 Percent of Total Breast Cancer Research Investment1
    • Awards Complement Ongoing Initiative, Which has Reached More Than 40 Million People to Date
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies. The awards are part of Pfizer’s Breast Cancer: A Story Half Told initiative, aimed at uncovering gaps in the public’s knowledge of MBC and bringing greater attention to the uniquemore...
  • 4/26/16 8:30 am EDT

    Pfizer research program only one to assess role of PCSK9 inhibitors in reducing risk of cardiovascular events in high-risk patients without history of cardiovascular events

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced patient enrollment completion in the global SPIRE-2 cardiovascular outcome trial for its investigational agent bococizumab. SPIRE-2 is evaluating the efficacy and safety of bococizumab compared to placebo in reducing the risk of major cardiovascular events among approximately 10,600 patients at high risk for cardiovascular disease - including those without a prior history of cardiovascular events – who are on highly-more...
  • 4/22/16 6:30 pm EDT

    Authors conclude no significant increase in serious neuropsychiatric adverse events with CHANTIX/CHAMPIX relative to placebo or nicotine patch

    Smokers treated with CHANTIX/CHAMPIX had significantly higher quit rates than those treated with bupropion, nicotine patch or placebo

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced results published in The Lancet from the largest clinical trial of approved smoking cessation medicines, called EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study). This smoking cessation trial included 8,144 adult smokers and was designed to compare the neuropsychiatric safety of CHANTIX®/CHAMPIX® (varenicline) and bupropion with placebo and nicotine patch in adult smokers withmore...
  • 4/21/16 2:00 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 28, 2016. To pre-register and access the live audio webcast, visit and click on the “Annual Meeting Webcast” button. Pre-registration begins today. A replay will be available through the first week of May 2016. more...
  • 4/19/16 8:00 am EDT

    Phase 3 Trial Provides Confirmatory Evidence for IBRANCE in the First-Line Setting and Will Support Global Regulatory Submissions

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced positive top-line results from the Phase 3 PALOMA-2 trial for IBRANCE® (palbociclib), an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6.1 The study met its primary endpoint by demonstrating an improvement in progression-free survival (PFS) for the combination of IBRANCE plus letrozole compared with letrozole plus placebo in post-menopausal women with estrogen receptor-positive,more...
  • 4/7/16 8:30 am EDT

    Experimental “Internet of Things” System Uses Connected Devices to Enable Remote Measurement of Health and Quality of Life in Real-Time

    Multi-Year Project Could Potentially Change How Clinical Trials are Conducted

    NEW YORK & ARMONK, N.Y.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and IBM (NYSE:IBM) today announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. Themore...
  • 4/6/16 11:00 am EDT

    Four-Dose Vial Will Help Address Infrastructure Challenges in Developing Countries

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). This new MDV presentation was developed to help maximize efficiency for health care workers by helping to significantly reduce storage requirements andmore...